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Summary
 
Although several cytokines, including tumor necrosis factor (TNF), can promote the growth of
dendritic cells (DCs) in vitro, the cytokines that naturally regulate DC development and func-
tion in vivo have not been well defined. Here, we report that membrane lymphotoxin (LT),
instead of TNF, regulates the migration of DCs in the spleen. LT
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 and LT
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, show markedly reduced numbers of DCs in the spleen. Unlike wild-
type mice and TNF
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 mice that have densely clustered DCs in the T cell zone and around
the marginal zone, splenic DCs in LT
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 mice are randomly distributed. The reduced num-
ber of DCs in lymphoid tissues of LT
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 mice is associated with an increased number of DCs
in nonlymphoid tissues. The number of splenic DCs in LT
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 mice is restored when addi-
tional LT-expressing cells are provided. Blocking membrane LT
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 in wild-type mice mark-
edly diminishes the accumulation of DCs in lymphoid tissues. These data suggest that mem-
brane LT is an essential ligand for the presence of DCs in the spleen. Mice deficient in TNF
receptor, which is the receptor for both soluble LT
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 trimers, have normal num-
bers of DCs. However, LT
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 mice show reduced numbers of DCs, similar to the mice
lacking membrane LT 
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. Taken together, these results support the notion that the signaling
via LT
 
b
 
R by membrane LT
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 is required for the presence of DCs in lymphoid tissues.
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oluble lymphotoxin (LT)
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 and TNF-
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 are structurally
related homotrimers (LT
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3
 
 and TNF-
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3
 
) that show
similar biological activities by binding to either of the two
defined TNF receptors, TNFR-I and TNFR-II, leading to
activation of a wide variety of inflammatory and immune
responses (1, 2). LT
 
a
 
 also exists as a membrane ligand by
binding to LT
 
b
 
 to form a membrane LT
 
a
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b
 
2
 
 heterotrimer
(membrane LT), which shows a high-affinity interaction
with LT
 
b
 
 receptor (LT
 
b
 
R) but only very low affinity for
TNFR-I or TNFR-II. The expression of membrane
LT
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b
 
2
 
 is detected on activated T, B, and NK cells,
whereas its receptor is expressed exclusively in nonlym-
phoid tissues (1, 3–5). The role of membrane LT and
 
LT
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R has been recently revealed by gene targeting. LT
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, and LT
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 mice all manifest profoundly de-
fective LN and Peyer’s patch development and altered
splenic structure and B cell follicles (6–9). Blocking mem-
brane LT function during mouse ontogeny by injection of
a soluble LT
 
b
 
R–Ig fusion protein or an anti-LT
 
b
 
 mAb to
pregnant wild-type (wt) mice resulted in the absence of pe-
ripheral lymphoid organogenesis in their progeny. Con-
versely, activation of LT
 
b
 
R with an agonistic mAb could
restore LN formation in the LT
 
a
 
2
 
/
 
2
 
 mice (10, 11). The
data prove that signaling via LT
 
b
 
R by membrane LT on
nonlymphocytes is required for lymphoorganogenesis and
the formation of the lymphoid tissue microenvironment.
The formation of microenvironment, such as B cell fol-
licles and T/B cell segregation in lymphoid tissue, may de-
pend on the expression of membrane LT on B cells (12–15).
LT may also regulate the localization of various lymphoid
and nonlymphoid cells by regulating a series of chemokines
in the lymphoid organs. For example, some chemokines
produced by stromal cells in B cell follicles direct the polar-
ization of the B cell follicles (16). Although the cell types
producing chemokines induced by LT in lymphoid tissue
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Abbreviations used in this paper
 
: BM, bone marrow; DCs, dendritic cells;
FDCs, follicular dendritic cells; LT, lymphotoxin; MLR, mixed leuko-
cyte reaction; MZs, marginal zones; wt, wild-type. 
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have not been identified, the expression pattern of chemo-
kines in lymphoid tissues resembles the distribution pattern
of follicular dendritic cells (FDCs) in B cell follicles and
lymphoid dendritic cells (DCs) in T cell zones (2, 16). Al-
though the role of membrane LT in the regulation of B
cell–related events and the maintenance of FDCs is well
defined, participation of this regulatory system in DC/T
cell events remains unclear. Interestingly, inhibition of the
membrane LT pathway has profound effects on several T
cell–based disease models, e.g., colitis (17), collagen-induced
arthritis (Browning, J.L., and R.A. Fava, unpublished ob-
servations), and induction of experimental autoimmune
encephalitis (Browning, J.L., and C.L. Nickerson-Nutter,
unpublished observation). T lymphocytes are important me-
diators of immunity, but their function is tightly regulated
by DCs (18, 19). One explanation for these observations
would be parallel regulation of DC/T cells, similar to that
of FDC/B cells, in an LT-dependent fashion (12–16).
Cytokines, such as GM-CSF and TNF, promote the
growth of DCs in vitro, but less is known about the regula-
tion of DC distribution and development in vivo (20, 21).
Injection of a pharmacological dose of polyethylene glycol–
modified GM-CSF into mice only expands the myeloid-
related DC subset (22). Interestingly, GM-CSF
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 or GM-
CSFR
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 mice show no significant impairment in the
development of splenic DCs, suggesting that this cytokine
is not absolutely required for DC development (23). Here,
we report that LT
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 or LT
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R
 
2
 
/
 
2
 
 mice show markedly
reduced numbers of splenic DCs but increased numbers of
DCs in nonlymphoid tissues. DCs are present in normal
numbers and distribution in TNF
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 and TNFR
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 mice.
Reconstitution of LT
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 mice with LT-expressing cells
restores the number of DCs in the spleen. On the other
hand, removal of LT-expressing cells or blocking mem-
brane LT in wt mice created an impaired DC migration
phenotype similar to that seen in LT
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 mice. These
findings strongly suggest that signaling via LT
 
b
 
R by mem-
brane LT is critical for the migration of DCs into lymphoid
tissues.
 
Materials and Methods
 
Animals.
 
LT
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 mice (backcrossed to C57BL/6 mice for
seven generations) and their wt littermates on a C57BL/6 back-
ground were bred under specific pathogen-free conditions as de-
scribed (6). LT
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R
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 mice were provided by Dr. Klaus Pfeffer
(Technical University of Munich, Germany) (8). TCR
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, RAG-1
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, TNFR-I
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, and TNF
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 mice as well as
CD3
 
e
 
-transgenic mice were purchased from The Jackson Labo-
ratory. B6-Ly5.1 mice were purchased from Frederick Cancer
Center, National Cancer Institute, Bethesda, Maryland. Animal
care and use were in accordance with institutional guidelines.
 
Cell Preparation and Staining.
 
Splenic DCs were treated and
collected basically according to the method developed by Inaba
et al. (24). In brief, spleen fragments were digested with 2 mg/ml
of collagenase and 100 
 
m
 
g/ml DNase for 30 min at 37
 
8
 
C and
then gently pipetted in the presence of 0.01 M EDTA for 1 min.
Single-cell suspensions were stained and analyzed by two-color
flow cytometry on a FACScan™ (Becton Dickinson). Biotiny-
 
lated anti-CD11c and CD11b (Mac-1), FITC-conjugated anti–
I-Ab, anti-CD11c, and anti-CD8
 
a
 
 antibody were all obtained
from PharMingen.
 
Immunohistology.
 
Spleens were harvested, embedded in OCT
compound (Miles-Yeda, Inc.), and frozen at 
 
2
 
70
 
8
 
C. Frozen sec-
tions (6–10 
 
m
 
m thick) were fixed in cold acetone. Endogenous
peroxidase was quenched with 0.2% H
 
2
 
O
 
2
 
 in methanol. After
washing in PBS, the sections were stained by first incubating with
FITC-conjugated anti-B220 for B cells and biotinylated anti-
CD11c for DCs (PharMingen) at 1:50–100 dilution. Horseradish
peroxidase–conjugated rabbit anti–FITC (DAKO Corp.) and al-
kaline phosphatase–conjugated streptavidin (Vector Labs., Inc.)
were added 1 h later. Color development for alkaline phosphatase
and horseradish peroxidase was performed with an alkaline phos-
phatase reaction kit (Vector Labs., Inc.) and with 3,3
 
9
 
-diami-
nobenzidine (Sigma Chemical Co.).
 
Generation of Reagents that Block Membrane LT Activity.
 
Anti-LT
 
b
 
antibody and some aspects of the control LT
 
b
 
R–Ig fusion pro-
tein used in this study have been previously described (4). The
method for the generation of LT
 
b
 
R–Ig fusion protein was used
as previously described with a minor modification (4). In brief,
cDNA encoding the extracellular domain of murine LT
 
b
 
R was
isolated by RT-PCR using the sense primer (5
 
9
 
-AAAGGC-
CGCCATGGGCCT-39) and the antisense primer (59-TTAA-
GCTTCAGTAGCATTGCTCCTGGCT-39) from mouse lung
mRNA, digested by NcoI/HindIII, and then fused to an IL-3
leader sequence in p30242 vector. The fusion fragment was then
subcloned into pX58 vector containing the IE-175 promoter and
the Fc portion of human IgG1, which was then transfected into
BHK/VP16 cells. The mouse LTbR–human Ig in culture super-
natants was purified on a protein A column. No difference can be
found between LTbR–human Ig in this preparation and a previ-
ous LTbR–Ig preparation in Chinese hamster ovary cells (4). To
block membrane LT activity in mice, the LTbR–Ig or anti-LTb
antibody (50–100 mg/injection) was given intraperitoneally, and
the number of DCs was determined 10–14 d later by either flow
cytometry or immunohistology.
Cell Transfer. Bone marrow (BM) cell or splenocyte transfer
was performed as previously described (12). In brief, BM-derived
DCs (BMDCs) from Ly5.1 mice were obtained by culturing BM
cells with GM-CSF (5 ng/ml) and IL-4 (2 ng/ml) according to
the procedure developed by Inaba et al. (25). BMDCs (5 3 106)
or splenocytes (5 3 107) were intravenously transferred into sub-
lethally irradiated recipient mice (600 rads). Spleens and LN cells
were collected for analysis within 24 h after transfer.
Mixed Lymphocyte Reaction. As stimulating cells, splenocytes
from wt or LTa2/2 mice were isolated by gentle pressure
through a cell strainer (Becton Dickinson), or spleen fragments
were treated with collagenase as described earlier (24). The stim-
ulating cells were irradiated at 2,000 rads. The LN cells from
BALB/c mice were collected by gentle pressure using a cell
strainer and cultured in a petri dish for 2 h. The nonadherent LN
cells were then harvested and used as the source of responding
cells. The different amounts of stimulating cells as indicated and 4 3
105 responding cells were cocultured for 72 h, and [3H]TdR at 1
mCi/ml was added during the last 18 h.
Results and Discussion
Markedly Reduced Numbers of DCs in LTa2/2 Mice but
Not in TNF2/2 Mice. TNF can promote the growth of
DCs in vitro (15, 16). To assess the role of TNF in the de-631 Wu et al.
Figure 1. Determination of DC number in mice deficient in LTa, TNF, or TNFR. Spleens from 6–10-wk-old wt (WT), TNF2/2, TNFR2/2, and
LTa2/2 mice were collected. (A) Splenocytes were stained for the DC marker (CD11c) and class II marker (I-Ab) as indicated. (B) The frozen spleen sec-
tions were stained for anti-CD11c antibody for DC (red) and anti-B220 antibody for B cells (brown). Data from one of five representative experiments is
shown. (C) Both lymphoid and myeloid DC subsets are reduced in LTa2/2 mice. The splenocytes were stained for DC subsets with CD11b/CD11c and
CD11c/CD8a as indicated.632 Requirement of LT for Dendritic Cells
velopment of DCs in vivo, splenocytes from TNF2/2 and
wt mice were stained for CD11c and MHC class II (I-Ab),
and the number of DCs in the preparation was determined
by flow cytometry. The total number of DCs in both types
of mice was similar, suggesting that TNF is not essential for
the development of DCs (Fig. 1 A and Table I). Interest-
ingly, the number of DCs in LTa2/2 mice was greatly re-
duced, especially for the CD11chighclass IIhigh subset (Fig. 1
A and Table I), suggesting a role for LTa in DC develop-
ment. Soluble LTa and TNF-a are structurally related ho-
motrimers (LTa3 and TNF-a3) that exhibit similar biologi-
cal activities by binding to the defined TNFRs (1), so
TNFR2/2 mice were used to determine the role of TNFR
in DC development (Fig. 1 and Table I). However, the
normal number of DCs in the spleens of TNFR2/2 mice
suggests that signaling via TNFR by either LTa3 or TNF-a3
is not essential for the presence of DCs in the spleen.
CD11c1 DC subsets preferentially migrate to distinct ar-
eas in the spleen (18, 19): myeloid DCs (CD8a2/CD11b1)
are mainly located in the marginal zones (MZs) of white
pulp, whereas lymphoid DCs (CD8a1/CD11b2) are pref-
erentially located in the T cell zones of white pulp. To
study whether LT or TNF preferentially regulates a subset
of DCs, the distribution of DCs and B cells in the spleens
of TNF2/2 mice and LTa2/2 mice was visualized histo-
logically (Fig. 1 B). Clusters of splenic DCs were readily
observed in the T cell zone and MZ of wt and TNF2/2
mice; however, only a few dispersed DCs were randomly
present in the spleens of LTa2/2 mice. The distribution
pattern and number of DCs visualized in situ closely corre-
lated to that measured by flow cytometry, which showed
that both myeloid and lymphoid DCs were proportionally
reduced in LTa2/2 mice (Fig. 1 C). Considering that my-
eloid and lymphoid DCs may be distinct populations of
DC subsets (18, 19), it is interesting to notice that the pres-
ence of both subsets was regulated by LT.
Signaling via LTbR by Membrane LTa1b2 Is Required for
the Presence of DCs. LTa2/2 mice lack both soluble LTa3
and membrane-associated LTa1b2, which bind to separate
receptors, TNFR and LTbR, respectively (1, 2). As the
number of DCs in TNFR-I2/2 mice was similar to that in
wt mice (Fig. 1 A and Table I), it was possible that mem-
brane LTa1b2, instead of soluble LTa3, was required for
the presence of DCs in the spleen. To test this hypothesis,
LTbR–Ig was used to block membrane LT activity in wt
adult mice, which resulted in the absence of FDCs in 1 wk.
Interestingly, the number of DCs but not lymphocytes in
the spleens was markedly reduced 10 d after the administra-
tion of a single dose of LTbR–Ig (Fig. 2 and Table I).
Moreover, the distribution pattern of the remaining DCs in
the spleen was similar to that in LTa2/2 mice.
Expression of LT has been detected primarily in acti-
vated T, B, and NK cells (1, 2). However, the percentage
of DCs in the spleen of TCR2/2BCR2/2 CD3e-trans-
genic mice or RAG-12/2 mice is not obviously reduced
(data not shown). In fact, the percentage of DCs in the
splenocytes of RAG12/2 mice is three- to fourfold higher
than that of wt mice (Fig. 2, A and B). This suggests that
the development of DCs could be independent of LT ex-
pression on T and B cells. To rule out whether the DC de-
velopment observed in RAG-12/2 mice might be occur-
ring via an LT-independent pathway, RAG-12/2 mice
were treated with LTbR–Ig for 10 d (Fig. 2 and Table I).
A significant reduction of splenic DCs (60–90% reduction)
was readily detected, demonstrating that LT-expressing
cells other than T and B cells control the migration of DCs
(Table I). Although NK cells in RAG12/2 mice were plau-
sible candidates for regulating DC migration in an LT-depen-
dent pathway, RAG-12/2 mice depleted of NK cells (with
300 mg of PK136, an anti-NK1.1 antibody) did not exhibit
reduced numbers of splenic DCs. Consistent with this data,
no reduction of DCs was detected in CD3e-transgenic
mice lacking both NK and T cells. It is likely that cells
other than T, B, and NK cells also express low levels of
LT, regulating the migration of DCs.
Murine LTbR–Ig may block ligands other than mem-
brane LT. It has been shown that human LTbR–Ig can
also bind to human LIGHT (homologous to lymphotoxins,
exhibits inducible expression, and competes with herpes
simplex virus glycoprotein D for HVEM, a receptor ex-
pressed by T lymphocytes), a recently identified mem-
brane-associated TNF family member (26). The biological
consequence of this binding is unclear. To exclude the po-
tential effect of LIGHT, an anti–murine LTb mAb, which
specifically binds to the LTb chain but not LIGHT, was
administered to wt mice. Such treatment also resulted in a
reduced number of DCs and their subsets similar to the ef-
Table I. Regulation of Splenic DCs by Membrane LT but Not 
by Soluble LTa3 or TNF-a3
Mice Treatment*
Percentage of‡ Presence of
DCs T cells FDCs
T/B 
zones
wt — 2.4 6 0.4 32 6 6 11
LTa2/2 — 0.6 6 0.2§ 34 6 3 22
TNFR-I2/2 — 3.7 6 0.4 27 6 3 21
TNFa/2/2 — 2.9 6 0.5 32 6 4 21
wt LTbR–Ig 0.9 6 0.2§ 32 6 8 21
wt control Ig 2.6 6 0.8 31 6 9 11
RAG-12/2 LTbR–Ig 3.7 6 0.2§ NA 22
RAG-12/2 control Ig 11 6 0.2 NA 22
*A single dose (50–100 mg) was administered intraperitoneally, and the
spleens from four to six mice were collected 10–15 d later for FACS
staining. Total number of splenocytes is comparable in wt and LTa2/2
mice (6).
‡Numbers represent cells with the indicated phenotypes expressed as
mean percentage 6 SD.
§Statistically significant differences (P , 0.01) between wt and LTa2/2
mice or between the LTbR–Ig-treated group and the control Ig–
treated group.
NA, not applicable due to the lack of T and B cells.633 Wu et al.
fect of LTbR–Ig (Fig. 3 A). Our data clearly indicate that
LTa1b2 is the ligand required for the presence of DCs in
the spleen. As ligands from the TNF family can bind to
more than one receptor, the number of splenic DCs in
LTbR2/2 mice was determined to directly address
whether signaling via LTbR is required for the presence of
DCs in lymphoid tissue. The number of DCs in these mice
was also lower than in wt mice (Fig. 3 B). Thus, the data
strongly suggest that signaling via LTbR by membrane LT
is essential for the presence of DCs in the spleen.
Figure 2. Reduced numbers of DCs in the mice treated with LTbR–Ig.
Wild-type (WT) mice (left) and RAG-12/2 mice (right) were treated with 50
mg human LFA-3–Ig (top) or LTbR–Ig (bottom). The spleens were collected
10 d after treatment. (A) The number of splenic DCs determined by flow cy-
tometry analysis. (B) Distribution of DC clusters determined by immunohistol-
ogy. The frozen spleen sections from these mice were stained for anti-CD11c
antibody (red) and anti-B220 antibody (brown). Data from one of six experi-
ments is presented.634 Requirement of LT for Dendritic Cells
Ineffective Migration of wt DCs into Spleens of LTa2/2
Mice. Fewer DCs in the lymphoid tissues of mice lacking
LT may be related to a reduction of DC progenitors in
BM, impaired migration, or an accelerated removal of
these cells. To test whether there was a deficiency in DC
progenitors or the growth of DCs in LTa2/2 mice, BM
cells from either wt or LTa2/2 mice were cultured by stan-
dard protocol using different doses of GM-CSF and IL-4
(25). The number of DC colonies and total number of
DCs was comparable between wt and LTa2/2 mice. In
addition, the number of DC colonies from wt mice was
not altered by coculture with LTbR–Ig (data not shown).
Together, the data suggest that LT is not an essential sur-
vival factor or growth factor for DCs or their progenitors.
It has recently been shown that LT and, to lesser degree,
TNF stimulates stromal cells to release chemokines, which
may determine the migration or segregation of T and B
cells in the spleen (16). It is possible that the migration of
DCs into lymphoid tissues of LTa2/2 mice is impaired
due to the lack of LT-mediated chemokines for DCs. If
the migration of DCs into lymphoid tissues is impaired in
LTa2/2 mice, the question would be where DCs accumu-
late in the absence of LT. If the BMDC development re-
mains functional in the absence of LT, we would expect
that the reduced number of DCs in lymphoid tissues in the
absence of LT might be associated with an increased num-
ber of DCs in nonlymphoid tissues. Interestingly, there is
an accumulation of lymphocytes around perivascular areas
in lungs, liver, pancreas, submandibular glands, kidneys,
and other tissues in LTa2/2, LTb2/2, and LTbR2/2 mice
(7–9). To test whether the number of DCs was also in-
creased in nonlymphoid tissues, DCs in lungs were quanti-
tated in wt and LTa2/2 mice. In contrast to the reduced
number of DCs in lymphoid tissues, the number of DCs in
lungs of LTa2/2 mice was much higher than in wt mice
(10.5 6 1.8 3 105 vs. 2.9 6 1.3 3 105). This suggests that
LT is required for the proper distribution of DCs.
To directly study whether the migration of DCs into the
spleen was impaired in LTa2/2 mice, DCs expanded from
the BM of Ly5.1 wt mice were transferred into LTa2/2
and C57BL/6 mice (Ly5.2), respectively. The number of
Ly5.1 DCs recovered from the spleens of wt mice was
two- to fourfold higher than that from LTa2/2 mice, al-
though both groups received similar numbers of DCs from
the same source (Fig. 4 A). Ly5.11CD11c2 donor cells,
mainly macrophages, in both groups were roughly the
same (Fig. 4 A). As the number of splenic DCs in wt mice
was not reduced within the first week after administration
of a high dose of LTbR–Ig, it is unlikely that transfer of
Ly5.1 DCs into LTa2/2 mice leads to the premature death
(,24 h) of these DCs.
It is possible that the splenic environment in LTa2/2
mice did not allow the efficient sequestration or migration
of DCs. The splenic environment essential for the localiza-
tion of DCs may include its architecture, the size and shape
of white pulps, and cytokines, such as chemokines, pro-
duced from the spleen. Altered splenic architecture and
smaller white pulp in LTa2/2 mice are readily visualized
defects that may structurally impair the migration of splenic
DCs into the proper area. However, short-term blockage
of membrane LT by LTbR–Ig in wt mice had no detect-
able impact on the architecture or size of white pulps, yet
this treatment still prevented the effective migration of
DCs into the T cell zone and B cell follicles (Fig. 2 and Ta-
ble I). This suggests that altered architecture itself is not the
primary cause of reduced migration of DCs into the
spleens of LTa2/2 mice. Interestingly, the altered T/B cell
segregation correlated with the altered localization of DCs
(Fig. 2) and with altered chemokine production in the ab-
sence of LT (16).
To study whether additional membrane LT can restore
the localization of DCs in the spleens of LTa2/2 mice, we
transferred LT-expressing lymphocytes and DCs from wt
mice into LTa2/2 mice. The altered splenic architecture
remained, but the number of CD11c1 cells in LTa2/2 re-
cipients was comparable to that in wt recipients 10 d after
transfer (Fig. 4 B), again suggesting that the overall archi-
tectural defect in LTa2/2 mice may not be the primary
cause of reduced number DCs in the spleen. It appears that
the microenvironment in the spleen required for the pres-
ence of DCs is rather flexible and can be altered in 1–2 wk.
Interestingly, the timing of the reduction of DCs is also
consistent with the maximum reduction of various
chemokines in the spleen 1–2 wk after administration of
LTbR–Ig (16). Thus, the data suggest that the reduced
number of DCs in LTa2/2 mice may be due, at least in
Figure 3. Signaling via LTbR by LTa1b2 is required for the presence
of DCs in the spleen. Splenocytes from mice treated with anti-LTb anti-
body or LTbR2/2 mice were enzymatically treated and stained for the
DC marker (CD11c) and class II marker (I-Ab) (left panels) or CD11c and
CD11b (right panels).635 Wu et al.
part, to the impaired migration of DCs that may be medi-
ated through altered chemokine production. The nature of
the LT-responsive stromal cells and the exact type of
chemokines remains to be determined.
LTa-mediated Microenvironment that Permits the Migration of
DCs Is Determined by BM-derived Cells. BM transfer in
long-term reconstitution provides a model to evaluate the
role of LTa in determination of the splenic microenviron-
ment that permits the migration of DCs. 6 wk after lethally
irradiated LTa2/2 mice were reconstituted with wt BM,
DCs were restored to a level similar to that seen in irradi-
ated wt mice reconstituted with wt BM (Fig. 5). This sug-
gests that the altered microenvironment that impairs the
migration of DCs is not developmentally fixed and that
LT-expressing BM cells could restore the migration of
DCs. In contrast, when lethally irradiated wt mice were re-
constituted with LTa2/2 BM, the number of DCs in the
spleen was reduced, as is seen in LTa2/2 mice or LTbR–
Ig-treated mice (Fig. 5). Therefore, the LTa-mediated
microenvironment that permits the migration of DCs is
primarily determined and maintained by LT-expressing
BM-derived cells.
Impaired Mixed Leukocyte Reaction in LTa2/2 Mice. To
examine whether reduced numbers of DCs in lymphoid
tissues of LTa2/2 mice could impair the overall function
Figure 5. Determination of the distribution of splenic DCs by BM-
derived cells in an LT-dependent fashion. BM reconstitution was per-
formed according to previously described methods (12). 6 wk after BM
reconstitution, spleens were collected and treated by using collagenase
(24). The cells were stained for anti-CD11c and anti–class II antibody.
Data from one of three experiments is presented.
LTa2/2 mice 10 d after cotransfer of LT-expressing splenocytes. 5 3 107
splenocytes from wt mice prepared by gentle pressure through a cell
strainer were transferred (.) into sublethally irradiated wt (WT) or
LTa2/2 mice as previously reported (12). The spleens were harvested 10 d
after transfer, and frozen sections were stained with anti-B220 (brown)
and anti-CD11c (red) to visualize the number and distribution of DCs.
Figure 4. Migration of wt DCs into the spleens of LTa2/2 mice in the
absence or presence of LT-expressing cells. (A) Impaired migration of
DCs in LTa2/2 mice. BMDCs (5 3 106) from Ly5.1 mice expanded in
vitro in the presence of GM-CSF and IL-4 were transferred to sublethally
irradiated LTa2/2 mice (right) and C57BL/6 mice (left). The spleens
were collected 24 h later and stained for Ly5.1 and CD11c. One of four
experiments is represented. CD11c2 cells from donor origin are compara-
ble in both groups (z0.25%). (B) Restoration of the splenic DCs in636 Requirement of LT for Dendritic Cells
of DCs, the ability of DCs in LTa2/2 mice to stimulate al-
logenic T cells was evaluated by mixed leukocyte reaction
(MLR). Mechanically separated splenocytes from LTa2/2
mice showed a decreased ability to stimulate allogenic T
cells in a dose-dependent manner (Fig. 6 A). To rule out
the possibility that reduced antigen-presenting activity in
the splenocytes of LTa2/2 mice is associated with the fail-
ure to release DCs from altered architecture of the spleen
using physical separation, spleen fragments from both
LTa2/2 mice and wt mice were subjected to collagenase
digestion to release DCs. The collagenase-treated spleno-
cytes from LTa2/2 mice showed profound defects (four-
to eightfold lower) in antigen-presenting activity compared
with those from wt mice, especially when the total spleno-
cytes was in the range of 0.2–1 3 105 cells (Fig. 6 B).
To exclude the impact from either of the developmental
defects in LTa2/2 mice, the splenocytes from LTbR–Ig-
treated C57BL/6 mice were collected by mechanical
pressure and used as stimulators. Severalfold reductions of
radiation count were readily detected in the LTbR–Ig-
pretreated group, as in the case of LTa2/2 mice (Fig. 6 C).
In general, the lower MLR closely correlated with the
lower number of DCs (Figs. 1, 2, and 6). The number of
other potential APCs, such as B cells, in the spleens of
LTa2/2 mice or mice treated with LTbR–Ig appears to be
comparable to that in wt mice. It was proposed a decade
ago that DCs are the principal stimulators of MLR in the
spleen (27, 28); our results further support the proposal, as
reduced numbers of DCs in LTa2/2 mice could account
for the impaired MLR.
Our results have revealed that membrane LT and LTbR
are the natural ligand–receptor pair essential for the pres-
ence of splenic DCs in vivo. LTa2/2 mice exhibit reduced
numbers of DCs in the spleen, whereas both TNF2/2 and
TNFR2/2 mice show normal numbers of splenic DCs,
suggesting that signaling via TNFR by either soluble LTa
or TNF is not an essential pathway for the regulation of
DCs in the spleen. The notion that membrane LT is an es-
sential ligand for the presence of DCs in the spleen is fur-
ther supported by the reduced number of DCs in the wt
spleen after the administration of either LTbR–Ig or anti-
LTb mAb. The results also suggest that signaling via LTbR
by membrane LT is required for the presence of DCs, as
LTbR is the only identified receptor for membrane LT.
Finally, the lower number of splenic DCs in LTbR2/2
mice confirms our hypothesis. In terms of the regulation of
development or migration of DCs in the spleen, an essen-
tial role of either soluble LTa3 or TNF-a3 has not been
demonstrated. However, TNF-a3 or LTa3 can coordinate
membrane LTa1b2 in the development of lymphoid tissues
(2, 10) and also may play a minor role in the migration of
DCs in some situations. Interestingly, recent studies re-
ported that high levels of soluble LTa3 were able to induce
chemokines and adhesion molecules in vitro (29). Ectopic
expression of LTa3 induces lymphocyte infiltration in non-
lymphoid tissue, suggesting that the overexpression of
LTa3 may still play a role in the migration of some lym-
phoid cells (30–32). Ectopic LT in LTa2/2 (RIPLT.LTa2/2)
mice also restored some LN, but a decreased number of in-
terdigitating DCs was apparent in the LN (31). Therefore,
proper expression of LT in the LN may also be required
for the presence of DCs in the LN.
The ineffective migration of DCs may account for the
reduced number of DCs in the spleens of mice lacking
membrane LT or its receptor: (a) compared with wt recipi-
ents, fewer donor DCs were present in the spleens of
LTa2/2 recipients; (b) a reduced number of DCs is not
developmentally fixed and can be repaired by LT-express-
ing cells; (c) the timing of altered numbers of DCs is con-
sistent with the altered expression of chemokines in the
spleen; (d) no significant impairment of DC growth or re-
duced DC progenitors can be detected; and finally, (e) DCs
accumulate in nonlymphoid tissues in both LTa2/2 and
LTbR2/2 mice, strongly supporting our notion that the
Figure 6. Impaired ability to stimulate allogenic T cells by splenocytes from LTa2/2 mice or wt mice treated with LTbR–Ig in mixed lymphocyte re-
action assay. Responder LN cells from BALB/c mice were cultured with a titration of irradiated splenocytes from C57BL/6 or LTa2/2 mice prepared by
mechanic pressure (A), collagenase digestion (B), or from mice pretreated with LTbR–Ig for 10 d (C). Data from one of four experiments is presented.637 Wu et al.
reduced number of DCs in the spleen is caused by im-
paired migration. Interestingly, fewer randomly distributed
DCs in the spleens of LTBR–Ig-treated mice could still
move to the T cell zone after intravenous injection of LPS,
suggesting that fine positioning of DCs in the spleen could
be regulated in an LT-independent fashion.
A number of chemokines are constitutively secreted in
the lymphoid organs in an LT-dependent fashion (16). Al-
tered distribution of T cells, B cells, and DCs in vivo may
be regulated by some chemokines. Whether proper distri-
bution of DCs and FDCs will facilitate T/B cell segrega-
tion remains to be determined. Although the expression of
several chemokines has been found to be downregulated in
the absence of LT, the exact chemokine that is essential for
the migration of DCs has yet to be identified. Which
chemokines are upregulated for directing DCs into non-
lymphoid tissues in the absence of LT is completely un-
known. Interestingly, the migration of most subsets of
macrophages in the spleen is largely unchanged in the ab-
sence of LT (Fig. 4 A), suggesting that the chemokines that
regulate the distribution of DCs may be distinct from those
that regulate the distribution of macrophages. It will be im-
portant to determine whether the differences in the migra-
tion patterns of macrophages and DCs may account for dif-
ferences in their biological activities. In addition to the
action of LT on stromal cells, it is also possible that direct
signaling via LTbR on DCs by membrane LT is required
for the migration of DCs in the spleen.
Reduced numbers of DCs may account for reduced
MLR, which is a DC-based T cell response. However, mi-
gration of DCs into lymphoid tissues for systemic immune
responses may be more important for the generation of
immune responses in vivo. In fact, after capturing antigens
outside lymphoid tissues, DCs must migrate into lymphoid
tissues to prime rare antigen-specific lymphocytes, which
constantly recirculate through peripheral lymphoid tissues
(18, 19). Regulation of the migration of DCs may provide
an additional means to manipulate immune responses, T
cell responses in particular. Consistent with that notion, we
have found that inhibition of membrane LT has profound
effects in several T cell–based disease models. For example,
administration of LTbR–Ig reduced severity of colitis (17),
collagen-induced arthritis, and experimental autoimmune
encephalitis (J.L. Browning, unpublished observation).
Clearly, the membrane LT/LTbR system provides an in-
teresting model to further study DC biology and DC-
mediated diseases.
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